🔗 Share this article

The first new treatments for gonorrhoea in decades are being described as a "huge turning point" in the fight against increasingly resistant strains of the bacteria, according to researchers.

A Global Challenge

Gonorrhoea infections are on the rise worldwide, with figures suggesting over 82 million new cases per year. Particularly high rates are seen in Africa and nations within the WHO's designated area, which includes China and Mongolia to New Zealand. Within England, cases have hit a record high, while rates across Europe in 2023 were significantly elevated compared to those in 2014.

“The authorization of fresh medications for gonorrhoea is an critical and opportune step in the context of rising global incidence, increasing antimicrobial resistance and the very limited treatment choices currently available.”

Public health authorities are increasingly worried about the rise in treatment-resistant strains. The World Health Organization has classified it as a "priority pathogen". Ongoing monitoring showed that resistance to standard treatments like cefixime and ceftriaxone increased dramatically between 2022 and 2024.

Two New Treatment Options Secure Clearance

Zoliflodacin, also known as a brand name, was cleared by the American regulatory agency in recent days for combating gonorrhoea. This infection can lead to significant complications, including the inability to conceive. Scientists believe that targeted use of this new drug will help delay the spread of drug resistance.

Gepotidacin, developed by the pharmaceutical company GSK, was also approved in concurrent days. This drug, which is employed against urinary tract infections, was demonstrated in studies to be successful in treating drug-resistant strains of the gonorrhoea bacteria.

A Unique Development Model

Zoliflodacin emerged from a new, not-for-profit approach for medication research. The non-profit organisation Global Antibiotic Research & Development Partnership worked alongside the pharmaceutical company Innoviva to develop it.

“This approval marks a major breakthrough in the therapy of superbug gonorrhoea, which until now has been staying ahead of antibiotic development.”

Testing Outcomes and Worldwide Availability

According to data released by a major medical journal, zoliflodacin eradicated the vast majority of uncomplicated infections. This establishes an comparable level with the current standard treatment, which involves an injection and a pill. The trial included over 900 volunteers from multiple nations including Belgium, the Netherlands, South Africa, Thailand and the US.

Through the arrangement of its development partnership, GARDP has the rights to make available and distribute the drug in numerous regions with limited resources.

Medical professionals directly involved have voiced optimism. Having a one-pill regimen like this is described as a "revolutionary step" for public health efforts. This is deemed crucial to reduce the burden of the disease for patients and to halt the transmission of untreatable gonorrhoea around the world.